Back to Search Start Over

Head to head comparison of 18F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging used in diagnosis of autoimmune rheumatic diseases.

Authors :
Li, Yuan
Zhou, Yunshan
He, Jing
Chen, Jinchuan
Zhu, Hua
Yang, Zhi
Wang, Qian
Li, Nan
Source :
Clinical Rheumatology; Nov2024, Vol. 43 Issue 11, p3497-3505, 9p
Publication Year :
2024

Abstract

Objectives: The aim of this study was to determine the performance of radionuclide-labeled fibroblast activation protein inhibitors (Al<superscript>18</superscript>F-NOTA-FAPI-04) PET/CT in patients with autoimmune rheumatic diseases (ARDs) and compare it with fluorine-18 (<superscript>18</superscript>F) labeled fluorodeoxyglucose (FDG) imaging. Methods: Fifty-eight participants with ARDs were prospectively enrolled from April 2022 to February 2024 and underwent dual-tracer PET/CT imaging. For both <superscript>18</superscript>F-FDG and Al<superscript>18</superscript>F-NOTA-FAPI-04 PET/CT, imaging findings were interpreted and compared. The clinical significance was compared between<superscript>18</superscript>F-FDG PET/CT and Al<superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging. Results: <superscript>18</superscript>F-FDG imaging was positive in 53 out of 58 cases (91.4%) while Al<superscript>18</superscript>F-NOTA-FAPI-04 imaging was positive in 55 out of 58 cases (94.8%). Overall positive rate of Al<superscript>18</superscript>F-NOTA-FAPI-04 imaging was as high as <superscript>18</superscript>F-FDG imaging (P = 0.625). <superscript>18</superscript>F-FDG imaging detected more lesions in lymph node, spleen, and bone marrow. Al<superscript>18</superscript>F-NOTA-FAPI-04 imaging detected more lesions in the lung, muscle, and tendon/ligament. There was no statistical difference of composing ratio of grades of clinical significance between two imaging modalities (χ<superscript>2</superscript> = 2.875, P = 0.238). The superior rate of Al<superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging was higher than <superscript>18</superscript>F-FDG imaging (P = 0.020). In subgroup of adult-onset Still's disease, <superscript>18</superscript>F-FDG imaging showed better performance than Al<superscript>18</superscript>F-NOTA-FAPI-04 imaging. In most of the other subgroup of ARDs, Al<superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging overperformed <superscript>18</superscript>F-FDG imaging. Conclusion: Both <superscript>18</superscript>F-FDG and Al<superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in ARDs. The detection capabilities of two tracers varied according to the involving organs of ARDs. In most of ARDs except adult-onset Still's disease, Al<superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging overperformed <superscript>18</superscript>F-FDG imaging. Key Points • <superscript>18</superscript>F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in diagnosing of ARDs. • <superscript>18</superscript>F-FDG PET/CT imaging detected more lesions in lymph node, spleen, and bone marrow. • <superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging detected more lesions in the lung, muscle, and tendon/ligament. • <superscript>18</superscript>F-NOTA-FAPI-04 PET/CT imaging overperformed<superscript>18</superscript>F-FDG in most subgroups of ARDs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07703198
Volume :
43
Issue :
11
Database :
Complementary Index
Journal :
Clinical Rheumatology
Publication Type :
Academic Journal
Accession number :
180373882
Full Text :
https://doi.org/10.1007/s10067-024-07155-4